ARV-471, an estrogen receptor (ER) PROTAC degrader, combined with palbociclib in advanced ER+/human epidermal growth factor receptor 2–negative (HER2-) breast cancer: Phase 1b cohort (part C) of a phase 1/2 study.

Authors

Erika P. Hamilton

Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN

Erika P. Hamilton , Anne F. Schott , Rita Nanda , Haolan Lu , Chi Fung Keung , Richard Gedrich , Janaki Parameswaran , Hyo S. Han , Sara A. Hurvitz

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

Phase I/II study of H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer.

First Author: Erika P. Hamilton

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

First-in-human first-in-class phase 1/2a study of the next generation CDK4-selective inhibitor PF-07220060 in patients (pts) with advanced solid tumors, enriched for HR+ HER2- mBC who progressed on prior CDK4/6 inhibitors and endocrine therapy.

First Author: Timothy A. Yap

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

A phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/ HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a nonsteroidal aromatase inhibitor (VIKTORIA-1).

First Author: Sara A. Hurvitz

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

The association of HER2 low expression with the efficacy of CDK4/6 inhibitor in hormone receptor positive HER2 negative metastatic breast cancer.

First Author: Kelvin K H Bao